396 related articles for article (PubMed ID: 10713685)
1. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
Green JE; Shibata MA; Yoshidome K; Liu ML; Jorcyk C; Anver MR; Wigginton J; Wiltrout R; Shibata E; Kaczmarczyk S; Wang W; Liu ZY; Calvo A; Couldrey C
Oncogene; 2000 Feb; 19(8):1020-7. PubMed ID: 10713685
[TBL] [Abstract][Full Text] [Related]
2. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
Shibata MA; Maroulakou IG; Jorcyk CL; Gold LG; Ward JM; Green JE
Cancer Res; 1996 Jul; 56(13):2998-3003. PubMed ID: 8674054
[TBL] [Abstract][Full Text] [Related]
3. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene.
Maroulakou IG; Anver M; Garrett L; Green JE
Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11236-40. PubMed ID: 7972041
[TBL] [Abstract][Full Text] [Related]
4. Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.
Hoenerhoff MJ; Shibata MA; Bode A; Green JE
Transgenic Res; 2011 Apr; 20(2):247-59. PubMed ID: 20549348
[TBL] [Abstract][Full Text] [Related]
5. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
6. Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice.
Liu ML; Shibata MA; Von Lintig FC; Wang W; Cassenaer S; Boss GR; Green JE
Oncogene; 2001 Apr; 20(16):2044-9. PubMed ID: 11360188
[TBL] [Abstract][Full Text] [Related]
7. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.
Li M; Lewis B; Capuco AV; Laucirica R; Furth PA
Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684
[TBL] [Abstract][Full Text] [Related]
8. A transgenic mouse model for the ductal carcinoma in situ (DCIS) of the mammary gland.
Schulze-Garg C; Löhler J; Gocht A; Deppert W
Oncogene; 2000 Feb; 19(8):1028-37. PubMed ID: 10713686
[TBL] [Abstract][Full Text] [Related]
9. Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP-2 expression.
Maroulakou IG; Shibata MA; Anver M; Jorcyk CL; Liu Ml; Roche N; Roberts AB; Tsarfaty I; Reseau J; Ward J; Green JE
Oncogene; 1999 Sep; 18(39):5435-47. PubMed ID: 10498897
[TBL] [Abstract][Full Text] [Related]
10. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage.
Shibata MA; Liu ML; Knudson MC; Shibata E; Yoshidome K; Bandey T; Korsmeyer SJ; Green JE
EMBO J; 1999 May; 18(10):2692-701. PubMed ID: 10329616
[TBL] [Abstract][Full Text] [Related]
11. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
12. Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
Aprelikova O; Tomlinson CC; Hoenerhoff M; Hixon JA; Durum SK; Qiu TH; He S; Burkett S; Liu ZY; Swanson SM; Green JE
PLoS One; 2016; 11(5):e0155262. PubMed ID: 27171183
[TBL] [Abstract][Full Text] [Related]
13. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression.
Yoshidome K; Shibata MA; Couldrey C; Korach KS; Green JE
Cancer Res; 2000 Dec; 60(24):6901-10. PubMed ID: 11156389
[TBL] [Abstract][Full Text] [Related]
14. Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3.
Turner-Ivey B; Smith EL; Rutkovsky AC; Spruill LS; Mills JN; Ethier SP
Breast Cancer Res Treat; 2017 Jul; 164(2):349-358. PubMed ID: 28484924
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of transforming growth factor betas during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5' flanking region fused to SV40 large T antigen.
Shibata MA; Jorcyk CL; Devor DE; Yoshidome K; Rulong S; Resau J; Roche N; Roberts AB; Ward JM; Green JE
Carcinogenesis; 1998 Jan; 19(1):195-205. PubMed ID: 9472712
[TBL] [Abstract][Full Text] [Related]
16. Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice.
Maroulakou IG; Shibata MA; Jorcyk CL; Chen XX; Green JE
Mol Carcinog; 1997 Oct; 20(2):168-74. PubMed ID: 9364206
[TBL] [Abstract][Full Text] [Related]
17. Expression of a viral oncoprotein during mammary gland development alters cell fate and function: induction of p53-independent apoptosis is followed by impaired milk protein production in surviving cells.
Li M; Hu J; Heermeier K; Hennighausen L; Furth PA
Cell Growth Differ; 1996 Jan; 7(1):3-11. PubMed ID: 8788028
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.
Liu R; Varghese S; Rabkin SD
Cancer Res; 2005 Feb; 65(4):1532-40. PubMed ID: 15735042
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging of the natural history of in situ mammary neoplasia in transgenic mice: a pilot study.
Jansen SA; Conzen SD; Fan X; Markiewicz EJ; Newstead GM; Karczmar GS
Breast Cancer Res; 2009; 11(5):R65. PubMed ID: 19732414
[TBL] [Abstract][Full Text] [Related]
20. Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression.
Rao T; Ranger JJ; Smith HW; Lam SH; Chodosh L; Muller WJ
Breast Cancer Res; 2014 Jan; 16(1):R11. PubMed ID: 24457046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
